ALNY vs. RPRX, BMRN, UTHR, IONS, MDGL, TEVA, GMAB, BGNE, VTRS, and SRPT
Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), BeiGene (BGNE), Viatris (VTRS), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Royalty Pharma (NASDAQ:RPRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Royalty Pharma presently has a consensus price target of $46.75, suggesting a potential upside of 77.15%. Alnylam Pharmaceuticals has a consensus price target of $216.19, suggesting a potential upside of 44.10%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Royalty Pharma is more favorable than Alnylam Pharmaceuticals.
Royalty Pharma has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Royalty Pharma has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals received 774 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.
54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Royalty Pharma had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 9 mentions for Royalty Pharma and 8 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.89 beat Royalty Pharma's score of 0.82 indicating that Royalty Pharma is being referred to more favorably in the media.
Royalty Pharma has a net margin of 35.70% compared to Royalty Pharma's net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 22.94% beat Royalty Pharma's return on equity.
Summary
Royalty Pharma beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alnylam Pharmaceuticals Competitors List
Related Companies and Tools
